The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database.
Kirsten L Rock, Paul Rees, David Morgan, Caroline S Copeland
Journal of psychopharmacology (Oxford, England) April 6, 2026 DOI: 10.1177/02698811261436573 via PubMed
Summary
AI-generated from the abstractMDMA is being studied as a treatment for PTSD, but many patients already take antidepressants. This retrospective case-control study used a national drug-death database to examine whether antidepressant use is linked to MDMA-related deaths. Among 1328 MDMA-positive deaths and 5312 matched controls, post-mortem detection of antidepressants was associated with lower odds of MDMA fatality compared to other drug-related deaths (adjusted odds ratio 0.595, 95% CI 0.491-0.722). However, when analyzing prescribed antidepressants, no significant association was found (adjusted odds ratio 0.838, 95% CI 0.688-1.021). The findings suggest an inverse association between antidepressant use and MDMA fatality, but the relationship is not straightforward.
Study at a glance
| Characteristics | Retrospective case-control study Peer reviewed |
|---|---|
| Sample size | 6,640 |
| Population | Deaths reported to the National Programme on Substance Use Mortality between 1997 and May 2023 |
| Topics | MDMA |
| Keywords | Antidepressant Case-control Fatality |
| Key finding | Post-mortem detection of antidepressants was associated with lower odds of MDMA fatality compared to other drug-related deaths, but prescribed antidepressants showed no significant association. |
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is being investigated as a new therapy for post-traumatic stress disorder (PTSD). With antidepressants as the first-line pharmacotherapy for PTSD, it is important to understand any drug-drug interactions between antidepressants and MDMA. This study aimed to investigate the association between antidepressant use and MDMA fatality using a drug-death database. A retrospective case-control study was performed using a dataset from the National Programme on Substance Use Mortality. Deaths reported between 1997 and May 2023 were extracted. Cases were defined as deaths with MDMA detected and were age- and sex-matched to controls, defined as deaths with no MDMA detected. Cases were analysed by post-mortem (PM) detection of antidepressants and prescription of antidepressants. Conditional logistic regression was performed, adjusted for confounders (polysubstance use and intentionality of death). A total of 1328 cases and 5312 matched controls for the PM analysis and 840 cases and 3360 matched controls for the prescribed analysis were included. In the PM analysis, after adjusting for potential confounders, antidepressant use was less likely in MDMA fatalities compared to other drug-related deaths (adjusted OR [aOR] 0.595 [95% Confidence interval (CI) 0.491-0.722]). In the prescribed analysis, there was no significant association between the prescription of antidepressants and MDMA fatalities (aOR 0.838 [95% CI 0.688-1.021]). An inverse association was found between antidepressant use and MDMA fatality in this retrospective case-control study using a drug-death database.